0000000000812822
AUTHOR
Divya Chugani
showing 3 related works from this author
Additional file 1: Table S1. of Standards not that standard
2015
Biobrick parts (Bb1 to Bb6) included in the different DNA constructions tested in this work. Table S2. Proteins displaying statistically significant alterations in their expression levels, as detected by iTRAQ analysis (DOCX 18 kb).
Development of an MCDA framework for evaluation and positioning of oncological treatments in clinical practice.
2019
95 Background: Ensuring that effective innovations are accessible in a timely and affordable manner to all cancer patients is a challenge that stakeholders face today. Several oncology frameworks (ASCO, ESMO, ICER, NCCN) have been developed to define and quantify the value of oncological therapies to support clinicians and patients at the time of selection and as a basis for decision-making. However, current frameworks only define treatment value in terms of clinical benefit, creating a need for one that allows holistic evaluation of treatments and supports decision-making in clinical practice. The ECO Foundation led this study to develop a reflective multi-criteria decision analysis (MCDA…
Standards not that standard
2015
There is a general assent on the key role of standards in Synthetic Biology. In two consecutive letters to this journal, suggestions on the assembly methods for the Registry of standard biological parts have been described. We fully agree with those authors on the need of a more flexible building strategy and we highlight in the present work two major functional challenges standardization efforts have to deal with: the need of both universal and orthogonal behaviors. We provide experimental data that clearly indicate that such engineering requirements should not be taken for granted in Synthetic Biology. Electronic supplementary material The online version of this article (doi:10.1186/s1303…